COMMUNIQUÉS West-GlobeNewswire

NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing
11/09/2025
TORONTO and HAIFA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a pioneering biopharmaceutical company developing exosome- [...]
HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
11/09/2025
Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , an artificial intelligence (“AI”)-powered medical technology company transforming ECGs/EKGs [...]
Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
11/09/2025
BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Great Place To Work ® and Fortune magazine have selected Roivant (Nasdaq: ROIV) for the 2025 Fortune Best Workplaces in BioPharma™ List . [...]
Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer
11/09/2025
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
InnovAge Named as One of the Nation’s Best Workplaces in Aging Services™ by Fortune® and Great Place to Work®
11/09/2025
A Leading Provider of PACE, Ranked in Top Tier of 2025 Best in Aging Services Category DENVER, Sept. 11, 2025 (GLOBE NEWSWIRE) -- InnovAge (NASDAQ: INNV), a leading provider of Program of All-Inclusive Care for the [...]
RESTEM to Host R&D Day Highlighting its Next-Generation Immunomodulatory Treatment for Autoimmune and Inflammatory Diseases
11/09/2025
Leading KOLs to discuss the unmet needs and current treatment landscapes of idiopathic inflammatory myopathy (IIM), ulcerative colitis (UC), rheumatoid arthritis (RA), and facioscapulohumeral muscular dystrophy (FSHD) [...]
Faraday Pharmaceuticals to Participate in Upcoming Investor Events
11/09/2025
Topline data from pivotal Phase 3 Iocyte AMI-3 trial expected in Q4 2025 SEATTLE, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on preventing heart [...]
Ipsen - Août 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
11/09/2025
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Ipsen - August 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
11/09/2025
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
OSE Immunotherapeutics et la Fondation FoRT annoncent la fin du recrutement dans Combi-TED, l’étude clinique de Phase 2 évaluant Tedopi® en combinaison avec nivolumab ou docétaxel dans le cancer du poumon non à petites cellules
11/09/2025
OSE Immunotherapeutics et la Fondation FoRT annoncent la fin du recrutement dans Combi-TED, l’étude clinique de Phase 2 évaluant Tedopi® en combinaison avec nivolumab ou docétaxel dans le cancer du poumon non à petites [...]
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer
11/09/2025
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 août 2025
11/09/2025
Nombre total de droits de vote et d’actions composant le capital social au 31 août 2025 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2025
11/09/2025
Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2025 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Guidance for the 2025/26 financial year
11/09/2025
ANNOUNCEMENT NO. 291 11 September 2025 Guidance for the 2025/26 financial year ChemoMetec today approved the annual report for 2024/25, including the guidance for 2025/26, which is considered inside information. For [...]
Annual Report 2024/25 - Growing revenue and EBITDA
11/09/2025
ANNOUNCEMENT NO. 292 11 September 2025 Annual Report 2024/25 (1 July 2024 - 30 June 2025) Growing revenue and EBITDA ChemoMetec’s revenue grew by 22% to DKK 495.6 million in 2024/25, and operating profit (EBITDA) [...]
Aesthetic Room Opens New Aesthetic Medicine Center in South Tyrol (Alto Adige) Near Merano and Bolzano
11/09/2025
Algund/Lagundo, South Tyrol (Alto Adige), Italy , Sept. 11, 2025 (GLOBE NEWSWIRE) -- Aesthetic Room , a new center for modern, minimally invasive aesthetic medicine , has officially opened in Algund , near Merano and [...]
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
11/09/2025
Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors FLORHAM PARK, N.J. and GARCHING, Germany and MUNICH, Germany, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cellectar [...]
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
11/09/2025
Pilot studies underway to advance IND-enabling preclinical development HOUSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270 [...]
Safety Shot Launches BONK Holdings to Build Treasury in $2.5 Billion BONK Ecosystem
11/09/2025
Company Forms New Subsidiary to House Digital Asset Strategy; Executes $5 Million Purchase to Increase BONK Treasury to Over $63 Million SCOTTSDALE, AZ, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT [...]

Pages